Chronic traumatic encephalopathy is a neurodegenerative disease that is believed to be a consequence of exposure to repetitive head impacts, including concussions and subconcussive injuries.
Recognizing the need for objective markers of brain injury, researchers have dedicated extensive efforts to developing concussion biomarkers.
The top three reasons for not reporting a concussion was similar between males and females.
May news includes ground-breaking FDA approvals, predictions of Alzheimer disease, and a possible biomarker for mild traumatic brain injury.
Blood protein analysis of plasma total tau has diagnostic use in Alzheimer disease. Could the same hold true for CTE?
April news includes tools to manage brain injury and predict recovery, new drug hits and misses, and an updated epilepsy classification system.
Research presented at IBIA 2017 looked at risk behavior in adolescents, return to work, and maladaptive emotion regulation following TBI.
March news includes possible brain tumor therapies, a study exploring mechanisms underlying demyelination-induced seizures, and VNS post stroke.
February news includes stroke risk with Alzheimer disease & migraine, neonatal hemorrhagic stroke, and head trauma in sports.
January news includes the first FDA-approved drug for spinal muscular atrophy, various epilepsy treatments & vitamin D’s impact on Alzheimer & headache.